Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107005 | 0.81 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1CETPACACB | |
| SCHEMBL4620171 | 0.76 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1CETPACACB | |
| SCHEMBL4620862 | 0.76 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1CETPACACB | |
| SCHEMBL24590336 | 0.73 | TSHR (0.44) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1145283 | 0.70 | — | — | |
| SCHEMBL21566909 | 0.69 | IDO1 (0.50) | — | |
| SCHEMBL3952347 | 0.69 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1CETPACACB | |
| SCHEMBL10033514 | 0.68 | CETP (0.47) | SLC1A3SLC1A2SLC1A1CETPACACB | |
| SCHEMBL20093550 | 0.68 | HPGD (0.37) | ACACBPTGS1PTGS2ALOX5TRPA1 | |
| SCHEMBL19251019 | 0.68 | ALDH1A1 (0.46) | SLC1A3SLC1A2SLC1A1ACACBPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878987-B2 | HSP70 modulators and methods for making and using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | HSPA2, HSP90AA1, HSP90AB1 | SLC1A3 4312/4885SLC1A2 3134/4885SLC1A1 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.